Top 8 Benefits of Mass Spectrometry Imaging Early in Drug Development
Mass spectrometry imaging (MSI) is a groundbreaking technology that provides visuals of complex biological samples to study a drug’s distribution and understand its potential toxicity. MSI can unlock crucial data and give scientists additional insights into drug discovery, diseases, and personalized medicine.
MSI is beneficial in early development and murine models across many therapeutic areas and is especially suited to oncology due to the availability of tissue. With MSI you can:
- Speed up and optimize the drug discovery process
- Visualize drug distribution in tissues and tissue sub-compartments
- Analyze samples for thousands of compounds at once
- Eliminate sensitivity and chemical alteration concerns
- Know whether efficacy is possible based on distribution
- Locate and identify metabolites to understand potential toxicity
- Improve understanding of pharmacokinetics and pharmacodynamics
- Save money and provide a competitive development edge
Download our infographic to learn more about the benefits of mass spectrometry imaging in oncology.
The Future of Small and Large Molecule Bioanalytics—Today
In bioanalysis, the future of small and large molecules offers exciting prospects for advancements in drug discovery, diagnostics, and therapeutics. With the increase of larger substances, emerging technologies, and new analytical approaches, drug developers are faced with both new opportunities to evaluate complex substances, and new challenges to address. Therefore, it’s important to learn which bioanalysis techniques are right for your drug.
In this white paper, you’ll learn about:
- Bioanalysis by molecular size
- Advancements in mass spectrometry
- Visualization and quantification of drug distribution
- The era of spatial imaging
- Novel technologies and adaptions
For more information about emerging technologies revolutionizing the field of bioanalysis, download our whitepaper today.
Validating the efficacy of a compound with spatial imaging
With the ever-changing drug development landscape, pharma and biotech companies have the challenging task to quickly and efficiently generate quality and unique data to file an IND. Spatial bioanalysis is a unique solution that can help you achieve this goal, while also enabling strategic and optimized decision making throughout your process.
Download this spatial bioanalysis white paper to gain insights from industry expert, Corinne Ramos, PhD. Discussion points include:
- Precision medicine development and added value
- Disease heterogeneity: Why is it? Why is it important? How do we visualize it?
Target discovery and development of composite biomarkers